There are 18 resources available
Perioperative immunotherapy for head and neck squamous cell carcinoma (HNSCC)
Presenter: Athanassios Argiris
Session: Immunotherapy for head and neck cancer: What, when and how long?
Resources:
Slides
Webcast
1087MO - A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous squamous cell carcinoma: First results from the AliCe study
Presenter: Juergen Becker
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
Recurrent/metastatic squamous cell carcinoma of the head and neck discussion
Presenter: Caroline Even
Session: ESMO Clinical Practice Guidelines 2
Resources:
Slides
Webcast
Recurrent/metastatic squamous cell carcinoma of the head and neck case presentation
Presenter: Cristina Gurizzan
Session: ESMO Clinical Practice Guidelines 2
Resources:
Slides
Webcast
858O - Minimal residual disease (MRD) diagnosed by a plasma tumor-agnostic circulating tumor DNA (ctDNA) assay after curative therapy in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) predicts disease relapse and survival
Presenter: Natasha Honoré
Session: Proffered Paper session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
Incorporating immunotherapy into the approach to locally advanced HNSCC
Presenter: Kevin Harrington
Session: Immunotherapy for head and neck cancer: What, when and how long?
Resources:
Slides
Webcast
Novel combinations in the non-curative HNSCC setting
Presenter: Brigette Ma
Session: Immunotherapy for head and neck cancer: What, when and how long?
Resources:
Slides
Webcast
853O - OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases using stereotactic ablative radiotherapy (SABR), the GORTEC 2014-04 “OMET” randomized phase II trial
Presenter: Juliette Thariat
Session: Proffered Paper session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
859MO - Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial
Presenter: Loren Michel
Session: Mini oral session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
855MO - Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma (HNSCC): Phase II trial evaluating the efficacy and the toxicity of Nivolumab (ADJORL1)
Presenter: Caroline Even
Session: Mini oral session - Head and neck cancer
Resources:
Abstract
Slides
Webcast